Robert W Lentz

11PUBLICATIONS
87CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsCancer cell biologyInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 28, 2026
Extended Follow-Up of Botensilimab Plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases.

|Aug 20, 2026
Clinical significance of WES-defined ERBB2 amplification in resectable colorectal cancer.

|Oct 31, 2025
Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.

Robert W Lentz, Julie Lang, Todd M Pitts

|Jun 19, 2025
Oligometastatic pancreatic cancer: current state of management and emerging therapies.

Andrii Khomiak, Nicole B Balmaceda, Sumaya A Ghaffar

|Jul 24, 2024
Risk Without Reward: Differing Patterns of Chemotherapy Use Do Not Improve Outcomes in Stage II Early-Onset Colon Cancer.

Jacob B Leary, Junxiao Hu, Alexis Leal

|Jun 13, 2024
A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer.

Robert W Lentz, Tyler J Friedrich, Patrick J Blatchford

Pageof 2

Frequent Collaborators

5 joint publications

Wells Messersmith

4 joint publications

Christopher H Lieu

3 joint publications

Todd M Pitts

3 joint publications

Sunnie S Kim